[{"orgOrder":0,"company":"Polynoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"POL-103A","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polynoma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Undisclosed"},{"orgOrder":0,"company":"Polynoma","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polynoma \/ US Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ US Food & Drug Administration"},{"orgOrder":0,"company":"Polynoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polynoma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Undisclosed"},{"orgOrder":0,"company":"Polynoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Seviprotimut-L","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polynoma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ Undisclosed"},{"orgOrder":0,"company":"Polynoma","sponsor":"TransCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"Seviprotimut-L","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polynoma \/ TransCode Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/ TransCode Therapeutics"}]